- Home
- IMTX vs CDNA Comparison
IMTX vs CDNA Comparison
Compare IMTX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- CDNA
- Stock Information
- Founded
- IMTX N/A
- CDNA 1998
- Country
- IMTX Germany
- CDNA United States
- Employees
- IMTX N/A
- CDNA N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- CDNA Medical Specialities
- Sector
- IMTX Health Care
- CDNA Health Care
- Exchange
- IMTX Nasdaq
- CDNA Nasdaq
- Market Cap
- IMTX 954.2M
- CDNA 1.1B
- IPO Year
- IMTX N/A
- CDNA 2014
- Fundamental
- Price
- IMTX $5.35
- CDNA $21.44
- Analyst Decision
- IMTX Strong Buy
- CDNA Buy
- Analyst Count
- IMTX 4
- CDNA 8
- Target Price
- IMTX $16.67
- CDNA $26.43
- AVG Volume (30 Days)
- IMTX 988.8K
- CDNA 851.0K
- Earning Date
- IMTX 11-18-2024
- CDNA 02-26-2025
- Dividend Yield
- IMTX N/A
- CDNA N/A
- EPS Growth
- IMTX N/A
- CDNA N/A
- EPS
- IMTX N/A
- CDNA N/A
- Revenue
- IMTX $128,824,447.00
- CDNA $312,775,000.00
- Revenue This Year
- IMTX $116.22
- CDNA $19.85
- Revenue Next Year
- IMTX N/A
- CDNA $11.34
- P/E Ratio
- IMTX N/A
- CDNA N/A
- Revenue Growth
- IMTX 52.53
- CDNA 5.26
- 52 Week Low
- IMTX $5.28
- CDNA $7.42
- 52 Week High
- IMTX $13.77
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- IMTX 21.22
- CDNA 43.79
- Support Level
- IMTX $7.00
- CDNA $21.09
- Resistance Level
- IMTX $7.42
- CDNA $25.95
- Average True Range (ATR)
- IMTX 0.41
- CDNA 1.61
- MACD
- IMTX -0.14
- CDNA 0.02
- Stochastic Oscillator
- IMTX 2.90
- CDNA 19.46
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.